CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Tuesday reported a loss of $68 million in its first quarter. On a per-share basis, the Chicago-based company said it had a loss of 40 cents.

Tempus AI posted Q1 revenue of $255.74M and a smaller-than-expected loss, signaling strong momentum in precision medicine. Analyst highlights $1B+ in total contract value and 25% topline growth ...

Tempus AI Inc. TEM during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said ...

Excluding that, Tempus is still FCF-negative and depends upon its $448 million cash reserve to cover expenses. With CapEx heavily constrained to lab upgrades and data infrastructure, reinvestment ...

Please go ahead. Thank you. Good afternoon and welcome to Tempus' first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

CHICAGO, May 06, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based health ...

Tempus has already deployed its Loop platform to prioritize drug targets in patient subpopulations with severe unmet needs for a large pharmaceutical company. By incorporating a lab-in-the-loop ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical ...